SFM
URGN icon

Sphera Funds Management’s UroGen Pharma URGN Stock Holding History

Sphera Funds Management’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-335,817
Closed -$8M – 97
2019
Q3 		$8M Buy
335,817
+27,440
+9% +$897K 1.24% 19
2019
Q2 		$11.1M Hold
308,377
– – 1.52% 14
2019
Q1 		$11.4M Buy
+308,377
New +$12.9M 1.04% 18

Other funds holding URGN

MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
HCM
Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sphera Funds Management's URGN Position: Q4 2019 in Review

Sphera Funds Management sold out of UroGen Pharma (URGN) in Q4 2019, closing a stake of 335,817 shares — an estimated $8M sold.

Sphera Funds Management first reported a position in URGN in Q1 2019 and held it in 3 quarters. The position peaked at $11.4M in Q1 2019. 86 funds tracked by Wall St. Rank hold URGN as of Q4 2019.

  • Sphera Funds Management reported no remaining UroGen Pharma position as of Q4 2019 after selling out during the quarter.
  • Sphera Funds Management sold 335,817 UroGen Pharma shares in Q4 2019, an estimated $8M.
  • Sphera Funds Management first reported a position in UroGen Pharma in Q1 2019 and held it in 3 quarters.
  • Sphera Funds Management's UroGen Pharma position peaked at $11.4M in Q1 2019.
  • 86 funds tracked by Wall St. Rank held UroGen Pharma as of Q4 2019.

Based on Sphera Funds Management's 13F filing for Q4 2019, filed 13 Feb 2020.